Nikon CeLL innovation

Nikon CeLL innovation Co., Ltd.(NCLi) operate reliable Cell and Gene therapy facility in Japan, offers broad selection of contract development and manufacturing(CDMO) services.

NCLi CDMO services are for early- to late-phase clinical and commercial cell and gene therapy products, to the biotech and Pharmaceutical customers.

Latest NewsNews >>

10 Feb. 2023: Heartseed announces first patient dosed in a phase 1/2 LAPiS Study with HS-001 - a cell therapy designed to restore heart function in people with advanced heart failure
HS-001 is manufactured by Nikon CeLL innovation.
14 Apr. 2020: Announcement of obtaining a license for manufacturing regenerative medicine products by Nikon CeLL innovation Co., Ltd.
1^st Mar. 2017: Web Renewal
7^th May 2015: Establish Nikon CeLL innovation Co., Ltd.

Latest EventEvent >>

12-14 Mar. 2020: The 19^th Congress of the Japanese Society for Regenerative Medicine (PACIFICO Yokohama)
26-28 Feb. 2020: 6^th Regenerative Medicine Expo OSAKA (INTEX Osaka)
9-11 Oct. 2019: BioJapan 2019 (PACIFICO Yokohama)
21-23 Mar. 2019: The 18^th Congress of the Japanese Society for Regenerative Medicine (Kobe)
20-22 Feb. 2019: Medical Japan2019 (INTEX Osaka)

GCTP ： Good Gene, Cellular, and Tissue-based Products Manufacturing Practice
GMP ： Good Manufacturing Practice
CDMO ： Contract Development and Manufacturing Organization